Genetics of Skin Cancer (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/11/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Basal Cell Carcinoma

Added text to state that intermittent dosing schedules of vismodegib have been shown to be effective in the reduction of basal cell carcinomas in the basal cell nevus syndrome population, although there has been no direct comparison between continuous dosing and intermittent dosing schedules (cited Dréno et al. as reference 137).

Melanoma

Added Zhen et al. as reference 76.

Added text to state that plexiform neurofibromas have also been reported in individuals with deleterious CDKN2A variants (cited Vanneste et al. as reference 81, Petty et al. as reference 82, Petronzelli et al. as reference 83, and Bahuau et al. as reference 84).

Revised text to state that the frequency of the TERT variant in melanoma families has not yet been investigated, but one study of 273 families with three or more cases of melanoma identified only one family (with 7 melanoma cases) that carried a c.-57 T>G promoter variant (cited Harland et al. as reference 93).

This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Psychosocial Issues in Familial Melanoma

Next section >
About This PDQ Summary